-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Moderna, Lowers Price Target to $70

Benzinga·05/02/2025 22:31:31
Listen to the news
UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $78 to $70.